NCT03579771View on ClinicalTrials.gov

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 26, 2018

Primary Completion Date

September 16, 2023

Study Completion Date

September 16, 2023

Conditions
Resectable CholangiocarcinomaStage IB Intrahepatic Cholangiocarcinoma AJCC v8Stage II Intrahepatic Cholangiocarcinoma AJCC v8Stage III Intrahepatic Cholangiocarcinoma AJCC v8Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
Interventions
DRUG

Cisplatin

Given IV

DRUG

Gemcitabine

Given IV

DRUG

Nab-paclitaxel

Given IV

Trial Locations (7)

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

30342

Emory Saint Joseph's Hospital, Atlanta

55905

Mayo Clinic, Rochester

77030

MD Anderson Cancer Center, Houston

97239

Oregon Health and Science University, Portland

98101

Benaroya Research Institute at Virginia Mason, Seattle

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER

NCT03579771 - Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer | Biotech Hunter | Biotech Hunter